Parallel to Biologics, another trend is the rapidly growing interest in Biosimilars. This is clearly fueled by the expiry of patents due on at least 48 biologics with a combined global market size of nearly $ 73 billion across the globe over the next decade. There is an increasing demand for low-cost medicines from healthcare players around the world as they struggle to contain soaring healthcare

Opportunities in this segment is obvious which is evident from some hard-core facts: